Podocyte-specific overexpression of GLUT1 surprisingly reduces mesangial matrix expansion in diabetic nephropathy in mice

American Journal of Physiology - Renal Physiology

Volumn 299, Issue 1, 2010, Pages

  Zhang, Hongyu ^a   Schin, MaryLee ^a   Saha, Jharna ^a   Burke, Kathleen ^a   Holzman, Lawrence B ^a   Filipiak, Wanda ^a   Saunders, Thomas ^a   Xiang, Minghui ^b   Heilig, Charles W ^b   Brosius III, Frank C ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Diabetic complications; Glucose; Metabolism; Type 2 diabetes; Vascular endothelial growth factor

Indexed keywords

FIBRONECTIN; GLUCOSE; GLUCOSE TRANSPORTER 1; PODOCIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL LYSATE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GLOMERULUS; GLUCOSE BLOOD LEVEL; IMMUNOBLOTTING; KIDNEY HYPERTROPHY; MESANGIUM CELL; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; TRANSGENIC MOUSE; WILD TYPE;

EID: 77953858179     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00021.2010     Document Type: Article

References (44)

1. American Registry of Pathology. Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology. New York: McGraw-Hill, 1968.
2. Auerbach AB, Norinsky R, Ho W, Losos K, Guo Q, Chatterjee S, Joyner AL. Strain-dependent differences in the efficiency of transgenic mouse production. Transgenic Res 12: 59-69, 2003.
3. Breyer MD, Bottinger E, Brosius FC, Coffman TM, Harris RC, Heilig CW, Sharma K. Mouse models of diabetic nephropathy. J Am Soc Nephrol 16: 27-45, 2005.
4. Brosius FC 3rd, Briggs JP, Marcus RG, Barac-Nieto M, Charron MJ. Insulin-responsive glucose transporter expression in renal microvessels and glomeruli. Kidney Int 42: 1086-1092, 1992.
5. Brosius FC, Heilig CW. Glucose transporters in diabetic nephropathy. Pediatr Nephrol 20: 447-451, 2005.
6. Chen SHK, Brosius FC III, Heilig CW. Diabetes increases glomerular GLUT1 and antisense-GLUT1 protects against diabetic glomerulosclerosis. J Am Soc Nephrol 14: 581A, 2003.
7. Cooper ME, Mundel P, Boner G. Role of nephrin in renal disease including diabetic nephropathy. Semin Nephrol 22: 393-398, 2002.
8. Coward RJ, Welsh GI, Koziell A, Hussain S, Lennon R, Ni L, Tavare JM, Mathieson PW, Saleem MA. Nephrin is critical for the action of insulin on human glomerular podocytes. Diabetes 56: 1127-1135, 2007.
9. Coward RJ, Welsh GI, Yang J, Tasman C, Lennon R, Koziell A, Satchell S, Holman GD, Kerjaschki D, Tavare JM, Mathieson PW, Saleem MA. The human glomerular podocyte is a novel target for insulin action. Diabetes 54: 3095-3102, 2005.
10. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 12: 993-1000, 2001.
11. El-Aouni C, Herbach N, Blattner SM, Henger A, Rastaldi MP, Jarad G, Miner JH, Moeller MJ, St-Arnaud R, Dedhar S, Holzman LB, Wanke R, Kretzler M. Podocyte-specific deletion of integrin-linked kinase results in severe glomerular basement membrane alterations and progressive glomerulosclerosis. J Am Soc Nephrol 17: 1334-1344, 2006.
12. Filipiak WE, Saunders TL. Advances in transgenic rat production. Transgenic Res 15: 673-686, 2006.
13. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51: 3090-3094, 2002.
14. Fredersdorf S, Weil J, Ulucan C, Birner C, Buttner R, Schubert T, Boger CA, Debl K, Muders F, Riegger GA, Luchner A. Vasopeptidase inhibition attenuates proteinuria and podocyte injury in Zucker diabetic fatty rats. Naunyn Schmiedebergs Arch Pharmacol 375: 95-103, 2007.
15. Garg P, Verma R, Nihalani D, Johnstone DB, Holzman LB. Neph1 cooperates with nephrin to transduce a signal that induces actin polymerization. Mol Cell Biol 27: 8698-8712, 2007.
16. Heilig C, Zaloga C, Lee M, Zhao X, Riser B, Brosius F, Cortes P. Immunogold localization of high-affinity glucose transporter isoforms in normal rat kidney. Lab Invest 73: 674-684, 1995.
17. Heilig CW, Brosius FC, Cunningham C. Role for GLUT1 in diabetic glomerulosclerosis. Expert Rev Mol Med 8: 1-18, 2006.
18. Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest 96: 1802-1814, 1995.
19. Heilig CW, Kreisberg JI, Freytag S, Murakami T, Ebina Y, Guo L, Heilig K, Loberg R, Qu X, Jin Y, Henry D, Brosius FC 3rd. Antisense GLUT-1 protects mesangial cells from glucose induction of GLUT-1 and fibronectin expression. Am J Physiol Renal Physiol 280: F657-F666, 2001.
20. Heilig CW, Liu Y, England RL, Freytag SO, Gilbert JD, Heilig KO, Zhu M, Concepcion LA, Brosius FC. D-glucose stimulates mesangial cell GLUT1 expression and basal IGF-I-sensitive glucose uptake in rat mesangial cells: implications for diabetic nephropathy. Diabetes 46: 1030-1039, 1997.
21. Henry DN, Busik JV, Brosius FC 3rd, Heilig CW. Glucose transporters control gene expression of aldose reductase, PKCα, and GLUT1 in mesangial cells in vitro. Am J Physiol Renal Physiol 277: F97-F104, 1999.
22. Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, Corat MA, Zeier M, Blessing E, Oh J, Gerlitz B, Berg DT, Grinnell BW, Chavakis T, Esmon CT, Weiler H, Bierhaus A, Nawroth PP. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 13: 1349-1358, 2007.
23. Katz EB, Stenbit AE, Hatton K, DePinho R, Charron MJ. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature 377: 151-155, 1995.
24. Kosugi T, Nakayama T, Li Q, Chiodo VA, Zhang L, Campbell-Thompson M, Grant M, Croker BP, Nakagawa T. Soluble-Flt-1 gene therapy ameliorates albuminuria, but accelerates tubulointerstitial injury in diabetic mice. Am J Physiol Renal Physiol 298: F609-F616, 2010.
25. Ku CH, White KE, Dei Cas A, Hayward A, Webster Z, Bilous R, Marshall S, Viberti G, Gnudi L. Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes 57: 2824-2833, 2008.
26. Lee MY, Lee EY, Lee BJ, Won CS, Koh JH, Shin JY, Shin YG, Cho BP, Chung CH. Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats. Yonsei Med J 48: 301-307, 2007.
27. Lennon R, Welsh GI, Singh A, Satchell SC, Coward RJ, Tavare JM, Mathieson PW, Saleem MA. Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1. Diabetologia 52: 1944-1952, 2009.
28. Lewko B, Bryl E, Witkowski JM, Latawiec E, Golos M, Endlich N, Hahnel B, Koksch C, Angielski S, Kriz W, Stepinski J. Characterization of glucose uptake by cultured rat podocytes. Kidney Blood Press Res 28: 1-7, 2005.
29. Marcus RG, England R, Nguyen K, Charron MJ, Briggs JP, Brosius FC 3rd. Altered renal expression of the insulin-responsive glucose transporter GLUT4 in experimental diabetes mellitus. Am J Physiol Renal Fluid Electrolyte Physiol 267: F816-F824, 1994. (Pubitemid 124005338)
30. Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts longterm urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia 42: 1341-1344, 1999. (Pubitemid 29500971)
31. Moeller MJ, Sanden SK, Soofi A, Wiggins RC, Holzman LB. Podocyte-specific expression of cre recombinase in transgenic mice. Genesis 35: 39-42, 2003. (Pubitemid 36150980)
32. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99: 342-348, 1997. (Pubitemid 27053474)
33. Sanden SK, Wiggins JE, Goyal M, Riggs LK, Wiggins RC. Evaluation of a thick and thin section method for estimation of podocyte number, glomerular volume, and glomerular volume per podocyte in rat kidney with Wilms' tumor-1 protein used as a podocyte nuclear marker. J Am Soc Nephrol 14: 2484-2493, 2003.
34. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 70: 1223-1233, 2006.
35. Schiffer M, Susztak K, Ranalletta M, Raff AC, Bottinger EP, Charron MJ. Localization of the GLUT8 glucose transporter in murine kidney and regulation in vivo in nondiabetic and diabetic conditions. Am J Physiol Renal Physiol 289: F186-F193, 2005.
36. Shen H, Smith DE, Yang T, Huang YG, Schnermann JB, Brosius FC 3rd. Localization of PEPT1 and PEPT2 proton-coupled oligopeptide transporter mRNA and protein in rat kidney. Am J Physiol Renal Physiol 276: F658-F665, 1999.
37. Shigehara T, Zaragoza C, Kitiyakara C, Takahashi H, Lu H, Moeller M, Holzman LB, Kopp JB. Inducible podocyte-specific gene expression in transgenic mice. J Am Soc Nephrol 14: 1998-2003, 2003.
38. Siu B, Saha J, Smoyer WE, Sullivan KA, Brosius FC 3rd. Reduction in podocyte density as a pathologic feature in early diabetic nephropathy in rodents: prevention by lipoic acid treatment. BMC Nephrol 7: 6, 2006.
39. Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55: 225-233, 2006.
40. Talior I, Yarkoni M, Bashan N, Eldar-Finkelman H. Increased glucose uptake promotes oxidative stress and PKC-Δ activation in adipocytes of obese, insulin-resistant mice. Am J Physiol Endocrinol Metab 285: E295-E302, 2003.
41. Weigert C, Brodbeck K, Brosius FC 3rd, Huber M, Lehmann R, Friess U, Facchin S, Aulwurm S, Haring HU, Schleicher ED, Heilig CW. Evidence for a novel TGF-beta1-independent mechanism of fibronectin production in mesangial cells overexpressing glucose transporters. Diabetes 52: 527-535, 2003.
42. Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, Saunders TL, Dysko RC, Kohno K, Holzman LB, Wiggins RC. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 16: 2941-2952, 2005.
43. Wolf G, Chen S, Ziyadeh FN. Perspectives in diabetes: from the periphery of the glomerular capillary wall toward the center of disease, podocyte injury comes of age in diabetic nephropathy. Diabetes 54: 1626-1634, 2005.
44. Zhang H, Saha J, Byun J, Schin M, Lorenz M, Kennedy RT, Kretzler M, Feldman EL, Pennathur S, Brosius FC 3rd. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. Am J Physiol Renal Physiol 295: F1071-F1081, 2008.